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Hematopoietic stem cells (HSCs) and their transplanta-
tion has proved itself as an effective approach to treat
different diseases. Since the first 3 cases of successful
allo-HCT in 1968, the number of allo-HCTs performed
annually has increased steadily over the past 3 decades
[1]. From the very beginning HSC demonstrates the
importance of individual/personal approach in all steps
of the management of the disease. One millionth trans-
plant is celebrated in 2013. Individual treatment plan is
unavoidable from the very first days after diagnose.
There is necessary to target the cure of the patient. For
that purpose right treatment options pretransplant are
necessary to choose. Many disease specific transplant
regimens are under development to improve transplant
outcome after HT. Depending on the disease and
patient’s status the source of the HSCs (autologous or
allogeneic) will be considered.
Choice of the stem cell source
Traditionally, hematopoietic stem cells were harvested
from the posterior iliac crests under general anaesthesia.
More recently, mobilized peripheral blood stem cells
have been increasingly used in both auto- and allo-
HSCT.
Hematopoietic stem cell transplantation presents a
unique opportunity to study the complex and systemic
effects of introducing a new genome in an individual.
The biological perturbations caused depend on the
genetic make-up of the donor and that of the recipient.
Validation of the role of each individual HLA locus was
established sequentially by comparing populations of
patients of different but known genetic composition
(monozygotic twins, siblings, haplotype-matched family
members and HLA-matched unrelated individuals).
The best donor remains an HLA-identical sibling
donor. The best unrelated donor has been shown to be
one who is matched, at high resolution for the major
polymorphic HLA loci. HLA-A, -B, -C, -DRB1 (8/8) are
all considered critical and many would consider an 8/8
matched donor as the gold standard. Genetic disparity
in particular at the HLA loci, between patient and
donor is a critical factor influencing transplantation
outcome.
Prognostic aspects – predicting the clinical
outcome of allogeneic hematopoietic stem cell
transplantation
One of the main factors influencing the clinical outcome
of allogeneic hematopoietic stem cell transplantation is
the restoration of a functional immune system. The
post-transplant period is characterized by multiple
immune defects that expose the patient to a high risk of
opportunistic infections and eventually, disease relapse.
The duration of this period may vary according to sev-
eral variables, including patient’s age and immune status
before transplant, the degree of donor compatibility, the
intensity of the conditioning regimen, the source of
stem cells, graft manipulation, and pharmacological
immune suppression. Measurable immune biomarkers
predicting the clinical outcome of HSCT await formal
validation.
In conclusion, hematopoietic stem cell transplantation
has demonstrated well the importance and role of per-
sonalized approach in the implementation of this tech-
nology in the treatment of different severe diseases.
However, in the era of predictive and molecular medi-
cine the practice of HSCT is still characterized by manyCorrespondence: Hele.Everaus@kliinikum.ee
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prognostic uncertainties. Therefore several questions
will have to be addressed with the attempt to develop-
ment approaches including the balance between the
effectiveness of the therapy, safety, costs and socio-eco-
nomic impact.
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